Ascendia specializes in the application of nano-technology approaches to developing novel pharmaceutical products that are challenging to formulate: EmulSol® is a technology for production of oil-in-water nano-emulsions; AmorSol® is a technology for the production of amorphous solid dispersions which greatly improves a drug's dissolution kinetics; and NanoSol® is a technology for the production of nano-sized crystals which significantly increases a drug's surface area available for dissolution. Ascendia uses these technologies to develop novel products for partners, and to build a pipeline of proprietary NDA 505(b)(2) products. Ascendia's lead proprietary product, ASD-002, is an injectable formulation of clopidogrel that addresses the unmet need for rapid, predictable P2Y12 platelet inhibition in patients with an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI).
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
three and more undisclosed